M2 macrophage polarization assay for immunotherapeutics assessment
03 / 16 / 2021
Get ready for the next in vitro SHUTTLE session!
Take advantage of new available seats on board or our upcoming shuttle session, scheduled by early May, to cost-effectively run your candidates on our robust M2 macrophage polarization assay thereby saving up to 25% full cost.
Our validated and well-characterized M2 polarization assay captures the main phenotypic and cytokinic M2 macrophage profile features, and therefore provides them as a wide array of valuable surrogates to evaluate effective drugs for their potential to disrupt the M2 polarization-induced signaling and/or to reprogram M2 to M1 macrophages, thereby alleviating the M2-mediated immunosuppression.
Immunosuppressive M2 macrophage phenotype features are relieved by PI3K signaling inhibition.
(A) Phenotypic M2 macrophage profile is characterized by higher expression of CD163 and CD209 and lower expression of CD86 than in M1-like macrophages. The PI3K inhibitor increases CD86 expression while decreasing that of CD163.
(B) Phenotypic IL10high IL6low IL1𝛃low M2-associated status is reversed by a PI3K inhibitor. HTRF-based quantification of IL10, IL6, IL1𝛃, and TNF⍺ levels released in the supernatants of LY294002-treated or untreated M2 macrophages during M2 polarization. The PI3K inhibitor treatment induces the proinflammatory cytokines including TNF⍺, IL6 and IL1𝛃, while decreasing the release of the anti-inflammatory IL10.
In vitro Macrophage Polarization Shuttle Session
Click & Register - Seating is limited!